Company Overview - Jianfan Biological Technology Group Co., Ltd. specializes in the research, production, and sales of biomaterials and high-tech medical devices [2] - The main products include various blood perfusion devices, dialysis solutions, disinfectants, and blood purification equipment [2] - The company has received multiple accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national champion in manufacturing [2] Financial Performance - For Q1 2025, the company reported a revenue of 548 million yuan, a year-on-year decrease of 26.40% [2] - The net profit for the same period was 189 million yuan, down 33.71% year-on-year, with a gross profit margin of 80.74% [2] Market Position - As of June 17, the company's stock closed at 21.16 yuan, with a rolling price-to-earnings (PE) ratio of 23.33 times [1] - The average PE ratio in the medical device industry is 49.80 times, with a median of 36.84 times, placing Jianfan Biological at the 51st position in the industry ranking [1][3] Shareholder Information - As of March 31, 2025, the number of shareholders for Jianfan Biological was 52,502, an increase of 5,451 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

证券代码：300529 证券简称：健帆生物 公告编号：2025-040 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于健帆转债 2025 年付息的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、"健帆转债"将于 2025 年 6 月 23 日按面值支付第四年利息，每 10 张健 帆转债（面值 1,000 元）利息为 15.00 元（含税）。 2、债权登记日：2025 年 6 月 20 日 3、除息日：2025 年 6 月 23 日 4、付息日：2025 年 6 月 23 日 5、付息年度：第 4 年 （一） 可转换公司债券简称：健帆转债 （二） 可转换公司债券代码：123117 （三） 可转换公司债券发行量：100,000.00 万元（10,000,000 张） 6、健帆转债的票面利率为：第一年为 0.30%，第二年为 0.50%，第三年为 1.00%，第四年为 1.50%，第五年为 1.80%，第六年为 2.00%。 7、健帆转债本次付息的债权登记日为 2025 年 6 月 20 日，凡在 2025 年 ...

Group 1 - The core viewpoint of the news highlights the financial performance and market position of Jianfan Biological Technology Group Co., Ltd, indicating a decline in revenue and net profit in the latest quarterly report [2] - As of June 5, the closing price of Jianfan Biotech was 21.77 yuan, with a rolling PE ratio of 24.01 times, and a total market capitalization of 17.386 billion yuan [1] - The company ranks 51st in the medical device industry, which has an average PE ratio of 50.97 times and a median of 36.67 times [1][3] Group 2 - Jianfan Biotech specializes in the research, production, and sales of biomaterials and high-tech medical devices, with key products including various blood purification devices and consumables [2] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 548 million yuan, a year-on-year decrease of 26.40%, and a net profit of 189 million yuan, down 33.71% year-on-year, with a gross profit margin of 80.74% [2] - As of March 31, 2025, the number of shareholders increased to 52,502, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

证券代码：300529 证券简称：健帆生物 公告编号：2025-039 债券代码：123117 债券简称：健帆转债 2、产品名称：一次性使用废液袋 3、注册证编号：粤械注准 20252100784 4、注册分类：Ⅱ类 5、注册证有效期：2025 年 5 月 27 日至 2030 年 5 月 26 日 健帆生物科技集团股份有限公司 关于新产品取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"公司"）于近日收到广东省药 品监督管理局颁发的《医疗器械注册证》，公司新产品一次性使用废液袋已取得 第二类医疗器械注册证。该新产品是血液净化治疗过程中的废液收集装置，具体 情况如下： 一、相关认证情况 1、注册人名称：健帆生物科技集团股份有限公司 力，将对公司未来的经营发展产生积极影响。 三、风险提示 上述产品实际销售情况取决于未来市场推广效果，公司目前尚无法预测其对 公司未来业绩的影响，敬请投资者注意投资风险。 特此公告。 健帆生物科技集团股份有限公司董事会 6、型号、规格：F10L、F7L、F5L、F3L、F ...

Company Overview - Jianfan Biological Technology Group Co., Ltd. specializes in the research, production, and sales of biomaterials and high-tech medical devices [2] - The main products include various blood purification devices and consumables, such as HA series blood perfusion devices and DX-10 blood purification machines [2] - The company has received multiple national recognitions, including being a key high-tech enterprise under the National Torch Program and a national technology innovation demonstration enterprise [2] Financial Performance - As of the first quarter of 2025, the company reported a revenue of 548 million yuan, a year-on-year decrease of 26.40% [2] - The net profit for the same period was 189 million yuan, down 33.71% year-on-year, with a gross profit margin of 80.74% [2] Market Position - The company's current price-to-earnings (PE) ratio is 23.87, significantly lower than the industry average of 49.11 and the industry median of 35.89 [1][3] - Jianfan Biological ranks 54th in terms of PE ratio within the medical device industry [1] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 52,502, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1]

特别提示： 健帆生物科技集团股份有限公司（以下简称"公司"）因 2024 年度权益分派方案 的实施，根据《健帆生物科技集团股份有限公司创业板向不特定对象发行可转换公司 债券募集说明书》及有关业务办理指南的规定，经向深圳证券交易所申请，公司可转换 公司债券（债券代码：123117；债券简称：健帆转债）自 2025 年 5 月 15 日至本次权 益分派的股权登记日（2025 年 5 月 23 日）暂停转股，具体内容详见公司于 2025 年 5 月 14 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于实施权益分派期间健帆转债 暂停转股的提示性公告》（公告编号 2025-035）。 根据相关规定，"健帆转债"将于公司 2024 年度权益分派股权登记日后的第一个 交易日（即 2025 年 5 月 26 日）起恢复转股。敬请健帆转债的债券持有人注意。 特此公告。 债券代码：123117 债券简称：健帆转债 证券代码：300529 证券简称：健帆生物 公告编号：2025-038 健帆生物科技集团股份有限公司 关于健帆转债恢复转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 ...

Core Viewpoint - The company Jianfan Bio is experiencing a decline in revenue and net profit, with a significant drop in both metrics year-on-year, while its stock performance shows a low price-to-earnings ratio compared to the industry average. Group 1: Company Performance - Jianfan Bio's stock closed at 22.07 yuan, up 1.42%, with a rolling PE ratio of 24.34, marking a new low in 14 days, and a total market capitalization of 17.625 billion yuan [1] - The latest quarterly report for Q1 2025 shows the company achieved operating revenue of 548 million yuan, a year-on-year decrease of 26.40%, and a net profit of 189 million yuan, down 33.71%, with a gross profit margin of 80.74% [2] Group 2: Industry Comparison - The average PE ratio for the medical device industry is 49.26, with a median of 36.71, placing Jianfan Bio at the 55th position in the industry ranking [1][3] - The industry average market capitalization is 105.99 billion yuan, while the median is 47.70 billion yuan, indicating Jianfan Bio's market cap is significantly lower than both the average and median [3] Group 3: Capital Flow - On May 19, 2023, Jianfan Bio saw a net inflow of 12.5401 million yuan in main funds, with a total inflow of 15.1556 million yuan over the past five days, indicating a generally positive capital flow trend [1]

关于因权益分派调整健帆转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、 债券代码：123117 债券简称：健帆转债 债券代码：123117 债券简称：健帆转债 证券代码：300529 证券简称：健帆生物 公告编号：2025-037 健帆生物科技集团股份有限公司 2、 调整前转股价格：39.43 元/股 3、 调整后转股价格：38.65 元/股 4、 转股价格调整生效日期：2025 年 5 月 26 日 5、 本次调整的原因：公司 2024 年度权益分派 一、关于健帆转债转股价格调整的相关规定 健帆生物科技集团股份有限公司（以下简称"公司"）于 2021 年 6 月 23 日向 不特定对象发行可转债 1,000 万张（债券简称：健帆转债，债券代码：123117）， 根据《健帆生物科技集团股份有限公司创业板向不特定对象发行可转换公司债券募 集说明书》（以下简称《募集说明书》）：在本次发行之后，当公司发生派送股票 股利、转增股本、增发新股（不包括因本次发行的可转债转股而增加的股本）、配 股以及派发现金股利等情况时，将按下述公式对转 ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-036 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 2024 年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、 公司 2024 年度权益分派方案为：以股权登记日 2025 年 5 月 23 日的总股本 （为扣除公司回购专用证券账户中股份数量后的总股本）为基数，向全体股东每 10 股派现金红利 8.00 元（含税），不送红股，不以资本公积金转增股本。截至本公告 日，公司总股本为 798,605,275 股，其中公司回购专用证券账户中股份数量为 24,242,894 股，因此公司 2024 年度权益分配的股本基数为 774,362,381 股。 2、 公司本次年度权益分派按照"分配比例不变"（即向全体股东每 10 股派发 现金红利人民币 8.00 元（含税），不送红股，不以公积金转增股本）的原则执行， 合计派发现金红利 619,489,904.80 元人民币（含税）。 3、 因回购股份不参与分红，本次权益分派实施后，根据股票市值不变原 ...

Company Overview - Jianfan Biological Technology Group Co., Ltd. specializes in the research, production, and sales of biomaterials and high-tech medical devices [2] - The main products include various blood perfusion devices, dialysis solutions, disinfectants, and blood purification equipment [2] - The company has received multiple accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national champion in manufacturing [2] Financial Performance - As of Q1 2025, the company reported revenue of 548 million yuan, a year-on-year decrease of 26.40% [2] - The net profit for the same period was 189 million yuan, down 33.71% year-on-year [2] - The gross profit margin stands at 80.74% [2] Market Position - The company's current price-to-earnings (PE) ratio is 23.84, compared to the industry average of 49.46 and the industry median of 36.16 [1][3] - Jianfan Biological ranks 53rd in terms of PE ratio within the medical device industry [1] - The total market capitalization of the company is 17.266 billion yuan [1]